Circular Genomics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10935 Alexandria Way Ste 201, San Diego,...Phone Number
(505) 357-0792Website
www.circulargenomics.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Circular Genomics
Circular Genomics is focused on advancing precision medicine through a novel circular RNA approach aimed at improving the diagnosis and treatment of psychiatric and neurological disorders. Their flagship product, MindLight, is the first antidepressant response test utilizing brain-derived biomarkers to predict patient responses to SSRI antidepressant treatment, thereby streamlining the treatment selection process. The company aims to enhance the treatment journey for individuals with mental health conditions by leveraging their expertise in circular RNA biomarkers. Circular Genomics is committed to fostering a better understanding of mental health and brain conditions to improve patient outcomes.Explore more
Circular Genomics Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Circular Genomics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Circular Genomics
Check out if Circular Genomics is spiking on competitors!
Funding: Get notified immidiatlly once Circular Genomics has new funding data
Circular Genomics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Circular Genomics launches new products
Earning: See what the market has to say on Circular Genomics recently announced quarterly report
Check if Circular Genomics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Circular Genomics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Circular Genomics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Circular Genomics
Compare insights from companies similar to Circular Genomics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Circular Genomics
$5.3M
11-50
Private
$28.1M
2021
Nikolaos MelliosCofounder & Chief Scientific Officer, Member of Board of Directors
Company Profile Activity
Activity Insights
Circular Genomics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Circular Genomics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Circular Genomics.
Circular Genomics financials insights
Gather financial insights about Circular Genomics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Angel/Seed
$4.5M
2024
Series A
$8.3M
2025
Other Financing Round
$250K
Series A
$15M
Circular Genomics Tech Stack
A closer look at the technologies used by Circular Genomics
Most Recent Scoops
Funding
Funding
Funding
Funding
Facilities Relocation / Expansion
Facilities Relocation/Expansion, Clinical Operations
New Hire
Executive Move
New Hire
Executive Move
Executive Moves, New Hire
Circular Genomics News & Media
Decode Health and Circular Genomics Announce a Research Collaboration to Advance Circular RNA Biomarkers in Multiple Sclerosis
The new initiative pairs Decode Health's AI-driven MS biomarker program with Circular Genomics' circular RNA platform to support earlier detection and monitoring of multiple sclerosis. The effort unites two teams with strong, complementary capabilities in RNA-driven precision medicine....Circular Genomics Appoints World-Renowned Expert in Neurochemistry and Alzheimer's Fluid Biomarkers Dr. Henrik Zetterberg to Scientific Advisory Board
Leading Alzheimer's Disease Researcher Joins to Advance Circular RNA Blood-Based Biomarker Platform for Neurodegenerative Diseases SAN DIEGO, April 24, 2026 /PRNewswire/ -- Circular Genomics, a biotechnology company revolutionizing neurological and psychiatric precision medicine through...Top 5 Firms Engineering Healthcare in the CNS Space | Inside Precision Medicine
Central nervous system (CNS) treatments are having a major comeback. These five precision medicine players plan to ride the resurgence.Circular Genomics Finalizes Exclusive IP Licenses with Leading Global Research Institutions to Advance circRNA Blood Test for Alzheimer's Disease
Agreements strengthen proprietary foundation, enhance partnering readiness, and support regulatory pathways for next-generation molecular diagnostics in neurology SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Circular Genomics, a molecular diagnostics company pioneering circular RNA...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Circular Genomics
Sign Up For FreeTo access detailed company insights
Circular Genomics is focused on advancing precision medicine through a novel circular RNA approach aimed at improving the diagnosis and treatment of psychiatric and neurological disorders. Their flagship product, MindLight, is the first antidepressant response test utilizing brain-derived biomarkers to predict patient responses to SSRI antidepressa... Read More
